Monthly Archives: September 2004


SEC Focusing on Drug Makers Disclosure_ Continuing Medical Ed Changes Tue, 28 Sep 2004 Evidence showing that drug manufacturers and the FDA concealed negative clinical trial data and deceived physicians, consumers, and shareholders about failure to demonstrate the safety and effectiveness of SSRI antidepressant drugs has caught the interest of […]

SEC Focusing on Drug Makers Disclosure_ Continuing Medical Ed Changes


Govt Prozac study Recommends MANDATORY Screening & Drugs – “Overdosed America”_OpEd NYT Sun, 19 Sep 2004 FDA’s Review of Safety & Efficacy Concerns in Anti-Depressant Use by Children is the subject of a second Congressional hearing by the House Energy & Commerce Subcommittee on Oversight / Investigations on September 23, […]

Govt Prozac study Recommends Mandatory Screening & Drugs – "Overdosed ...


18% decrease SSRI use in Youth – NYT / Suicide Risk Not New – Globe / Prozac no different Tue, 21 Sep 2004 The FDA failed to stop drug manufacturers from flooding the air waves and the scientific literature with false and scientifically invalid claims-based on partial data. “The FDA […]

18% decrease SSRI use in Youth – NYT / Suicide ...



AHRP Press Briefing September 14, 2004 Antidepressants and Suicide-Related Risks for Children Scientists’ Presentations at AHRP Press Briefing in Conjunction with FDA Hearings: Peter Mansfield, MD, University of Adelaide (Australia), Director of Healthy Skepticism discussed the illusion of potency in light of the meta-analyses in the British Medical Journal (which […]

Antidepressants & Suicide-Related Risks: 9/14/04 AHRP Press Briefing


ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) www.ahrp.org ***PRESS STATEMENT*** Re: The FDA & Concealment of Suicide-Related Risks of Antidepressants Date: September 14, 2004 Contact: Vera Hassner Sharav, President   We are witnessing the unraveling of a system that was intended to ensure that marketed drugs met high safety standards; that […]

AHRP Press Statement – FDA & SSRI Suicide Risk 9/14/04


Scientists' Presentations at AHRP Press Briefing in Conjunction with FDA Hearings:

  • Peter Mansfield, MD, University of Adelaide (Australia), Director of Healthy Skepticism discussed the illusion of potency in light of the meta-analyses in the British Medical Journal (which he co-authored) and the Lancet.
    Dr. Mansfield's power point presentation
  • Peter Breggin, MD, a psychiatrist with a sub-specialty in clinical psychopharmacology, who was among the first to recognize adverse antidepressant drug reactions
    Dr. Breggin's presentation
  • Lawrence Diller, MD, a pediatrician and family therapist who has evaluated and treated more than 2,500 children
    Dr. Diller's presentation
  • Stefan Kruszewski, MD, a clinical and academic psychiatrist, and Associate Medical Director of Physicians' Health Programs, Pennsylvania Medical Society
    Dr. Kruszewski's presentation
  • David Healy, MD, Director of the North Wales Department of Psychological Medicine and Visiting Professor, University of Toronto,

AHRP Press Briefing: Antidepressants and Suicide-Related Risks for Children



We are witnessing the unraveling of a system that was intended to ensure that marketed drugs met high safety standards; that physicians were informed about potential, serious adverse drug effects - so that they would prescribe judiciously; and that the integrity of the scientific literature was preserved. But that system has been hijacked by the drug industry - which has infected medical practice and medical research with detail men and informercials that make false claims while manipulating partial data to conceal adverse drug effects.

Press Statement – FDA & Concealment of Suicide-Related Risks of ...


FDA’s Waiting Game Exposes Children to Preventable Risks Comments by Vera Hassner Sharav President The Alliance for Human Research Protection Submitted to FDA Advisory Committee Psychopharmacological Drugs Advisory Committee and Pediatric Subcommittee Drugs Advisory Committee September 13-14, 2004 Meeting RE: Suicidality Associated with Antidepressant Drug Treatment The Alliance for Human […]

FDA's Waiting Game Exposes Children to Preventable Risks – 9/04 ...


ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) 142 West End Ave. Suite 28P, New York, NY 10023 ***PRESS RELEASE*** September 11, 2004 Contact: Vera Hassner Sharav, President, AHRP Tel. No: 212-595-8974 Cell: 917-375-5083 ***AHRP PRESS BRIEFING*** Re: Antidepressants and suicide-related risks for children When: September 14, 2004, 12:00 P.M. Where: Holiday […]

AHRP Press Briefing Re: Antidepressant Drug Risks